← All trials
NCT02640755
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 28, 2016
- Primary completion
- Dec 21, 2016
- Completion date
- Feb 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 6
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- The Christie NHS Foundation TrustOverall official - principal investigator
- IQVIACollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.